Drucker Wealth 3.0 LLC Sells 2,440 Shares of Amgen Inc. $AMGN

Drucker Wealth 3.0 LLC trimmed its position in shares of Amgen Inc. (NASDAQ:AMGN) by 27.2% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 6,515 shares of the medical research company’s stock after selling 2,440 shares during the period. Drucker Wealth 3.0 LLC’s holdings in Amgen were worth $1,838,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Brighton Jones LLC increased its position in Amgen by 23.5% during the 4th quarter. Brighton Jones LLC now owns 27,468 shares of the medical research company’s stock worth $7,159,000 after buying an additional 5,226 shares during the period. Sivia Capital Partners LLC boosted its stake in shares of Amgen by 10.6% in the 2nd quarter. Sivia Capital Partners LLC now owns 1,186 shares of the medical research company’s stock valued at $331,000 after purchasing an additional 114 shares in the last quarter. Balboa Wealth Partners lifted its stake in shares of Amgen by 4.6% in the 2nd quarter. Balboa Wealth Partners now owns 986 shares of the medical research company’s stock valued at $275,000 after acquiring an additional 43 shares during the last quarter. Beverly Hills Private Wealth LLC raised its holdings in Amgen by 1.9% in the 2nd quarter. Beverly Hills Private Wealth LLC now owns 1,969 shares of the medical research company’s stock valued at $550,000 after buying an additional 37 shares during the last quarter. Finally, Schnieders Capital Management LLC. increased its holdings in Amgen by 29.3% in the second quarter. Schnieders Capital Management LLC. now owns 25,859 shares of the medical research company’s stock valued at $7,220,000 after purchasing an additional 5,853 shares during the period. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, SVP Nancy A. Grygiel sold 3,139 shares of the stock in a transaction dated Thursday, November 20th. The shares were sold at an average price of $337.26, for a total transaction of $1,058,659.14. Following the completion of the sale, the senior vice president directly owned 7,225 shares in the company, valued at approximately $2,436,703.50. This represents a 30.29% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 0.76% of the stock is owned by insiders.

Amgen Trading Up 1.1%

Shares of AMGN opened at $373.36 on Wednesday. The firm’s 50 day simple moving average is $339.62 and its 200 day simple moving average is $314.83. Amgen Inc. has a 1-year low of $261.43 and a 1-year high of $385.12. The company has a debt-to-equity ratio of 5.78, a current ratio of 1.14 and a quick ratio of 0.90. The company has a market capitalization of $201.05 billion, a P/E ratio of 26.24, a P/E/G ratio of 3.78 and a beta of 0.46.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.76 by $0.53. Amgen had a return on equity of 148.37% and a net margin of 20.98%.The firm had revenue of $9.87 billion during the quarter, compared to analysts’ expectations of $9.46 billion. During the same period in the prior year, the business earned $5.31 EPS. The company’s revenue for the quarter was up 8.6% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. Sell-side analysts forecast that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.

Amgen Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, February 13th will be issued a $2.52 dividend. This is a positive change from Amgen’s previous quarterly dividend of $2.38. This represents a $10.08 annualized dividend and a dividend yield of 2.7%. The ex-dividend date is Friday, February 13th. Amgen’s dividend payout ratio (DPR) is 70.84%.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on AMGN shares. Morgan Stanley lifted their target price on shares of Amgen from $304.00 to $309.00 and gave the stock an “equal weight” rating in a research note on Wednesday, February 4th. Daiwa Securities Group raised their price target on shares of Amgen from $370.00 to $410.00 and gave the company an “outperform” rating in a research report on Tuesday, February 10th. Argus upped their target price on shares of Amgen from $360.00 to $400.00 and gave the stock a “buy” rating in a research note on Friday, February 6th. BMO Capital Markets raised their price target on shares of Amgen from $335.00 to $372.00 and gave the company an “outperform” rating in a research report on Wednesday, December 3rd. Finally, Deutsche Bank Aktiengesellschaft upped their price objective on Amgen from $285.00 to $295.00 and gave the company a “hold” rating in a research note on Thursday, February 5th. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, ten have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $354.04.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.